OSE Immuno - Positive DSMB review on the ongoing Ph2 in UC
Today, OSE announced that the trial's Independent Drug Safety Monitoring Board (DSMB) provided a positive recommendation on the continuation until its completion of the Phase 2 clinical trial of IL-7 Receptor antagonist Lusvertikimab (OSE-127) in ulcerative colitis (UC).In May, a positive interim futility analysis was already announced in the prespecified first 50 patients (1/3rd of patients). Top-line results after the induction phase are still expected later this year.No impact on estimates and valuation. We stick to our Buy rating and TP. Most notable catalysts this year include the readouts from the Ph1 dose expansion study in colorectal/endometrial cancer (BI 765063)Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.